BRAF inhibitor activity in V600R metastatic melanoma – Response
European Journal of Cancer2013Vol. 49(7), pp. 1797–1798
Citations Over TimeTop 19% of 2013 papers
Oliver Klein, Arthur Clements, Alexander M. Menzies, Sandra O’Toole, Richard Kefford, Georgina V. Long
Related Papers
- → BRAF inhibitor activity in V600R metastatic melanoma – Response(2013)18 cited
- → T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients(2014)1 cited
- → 98 Treating Metastatic Melanoma With the BRAF Inhibitor Vemurafenib and Mechanisms of Resistance(2012)
- → 330 INVITED The Development of Vemurafenib for BRAF-mutated, Metastatic Melanoma(2011)
- → Supplementary figure legend from Correlating Surrogate Endpoints with Overall Survival at the Individual Patient Level in BRAF<sup>V600E</sup>-Mutated Metastatic Melanoma Patients Treated with Vemurafenib(2023)